Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.

Leukemia & lymphoma - 1 Dec 2024

Tashakori Mehrnoosh, Yohe Sophia, Linden Michael A, McKenna Robert W

Abstract excerpt

In 2022, the World Health Organization (WHO) and International Consensus Classification (ICC) recognized TP53 as an entity-defining alteration in myeloid neoplasms, yet with differing criteria that could lead to discrepant diagnoses and affect clinical trial eligibility. We studied 67 patients with TP53 mutant myeloid neoplasms, reclassifying them using both criteria. While most cases fulfill the criteria for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Minnesota

Share to Mutation

Share to Myeloproliferative Disorders

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 39257174
DOI: 10.1080/10428194.2024.2400213

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.PMID 39257174Read ↗

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.Semantic proximity Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.Semantic proximity Read ↗

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortSemantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.Semantic proximity Read ↗

A line in shifting sand: Can we define and target TP53 mutated MDS?Semantic proximity Read ↗

Navigating prognostic stratification and approach to TP53 -mutated myeloid neoplasms.Semantic proximity Read ↗

Overall survival in TP53-mutated AML and MDS.Semantic proximity Read ↗

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.Semantic proximity Read ↗

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classificationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.